We are delighted to announce that Pearce IP’s Founder and CEO, Naomi Pearce has been selected as a finalist for the 2024 IP Partner of the Year at the Lawyers Weekly Partner of the Year Awards.
Pearce IP BioBlast w/e 26 April 2024
29 APR 2024 | KR | Samil Pharmaceutical to Launch Samsung Bioepis’ Aflibercept in Korean Market from 1 May The Korean Biomedical Review has reported that Samil Pharmaceutical...
Pearce IP BioBlast w/e 19 April 2024
21 APR 2024 | US | Xbrane to Resubmit BLA for Ranibizumab Biosimilar following FDA CRL On 21 April 2024, Swedish biosimilar developer Xbrane announced that the FDA issued a...
The Carpark Patent Saga Continues – Infringement and Best Method
The Full Federal Court has overturned the primary judge’s decision on construction and infringement (with respect to PinForce version 3) but upheld the primary judge’s decision on best method, in the latest case to be heard and decided in the long-running patent disputes between arch rivals in the field of carpark overstay detection.
Pearce IP BioBlast w/e 12 April 2024
12 APR 2024 | US | Six Regeneron Aflibercept US Patent Infringement Actions to be Centralized in West Virginia On 11 April 2024, the United States Judicial Panel on...
H.A.S. Real Estate Wins The (Branding) War But Loses The (Indemnity Costs) Battle
In a decision handed down on 2 April 2024 by the Full Federal Court, H.A.S Real Estate (H.A.S) has failed in its application for indemnity costs. The Court’s unanimous judgment by Justices Yates, Markovic and Kennett emphasises the critical importance of ensuring that an offer of compromise aligns with the orders and remedies which a party can receive through the court process.
Pearce IP BioBlast w/e 05 April 2024
05 APR 2024 | Samsung Bioepis Commences Phase 3 Trials for Keytruda® Biosimilar On 5 April 2024, Samsung Bioepis announced the commencement of Phase 3 clinical trials for SB27,...
Pearce IP BioBlast w/e 29 March 2024
28 MAR 2024 | US | Celltrion Launches US Pediatric High Concentration Adalimumab Biosimilar On 28 March 2024, the Korea IT Times reported the US launch of Celltrion’s pediatric...
Restored, but only just! Quirks of New Zealand law almost stump Avalyn Pharma’s quest for patent protection
On 8 March 2024, Justice Burley of the Federal Court issued the latest in a series of decisions relating to the patent-eligibility of Aristocrat’s electronic gaming machine (EGM) patents. Unfortunately it does not resolve the legal uncertainty created by the High Court’s split decision on the matter in 2022. What next?
ABC Law Report Podcast features Pearce IP Founder Naomi Pearce
Pearce IP’s Founder Naomi Pearce discusses this topic on prime time radio with ABC Law Report Host Damian Carrick, in light of the recent decision of the Federal Court in Allied Pumps Pty Ltd v LAA Industries Pty Ltd handed down in late November last year.
Pearce IP BioBlast w/e 22 March 2024
22 MAR 2024 | AU | Samsung Bioepis Seeks to Revoke Janssen’s Stelara® (ustekinumab) Patents in Australian Court On 22 March 2024, the first case management hearing was held...
MMD unsuccessful again on appeal in infringement case against Camco
MMD has been unsuccessful again in their infringement suit against Camco Engineering and also in their allegation that Camco contravened the Australian Consumer Law.
Pearce IP BioBlast w/e 15 March 2024
15 MAR 2024 | AU | November 2023 PBAC Public Summary Documents Feature Biopharma On 15 March 2024, the Australian Department of Health and Aged Care published the public summary...
Aristocrat down to the felt in the Federal Court on remitter
On 8 March 2024, Justice Burley of the Federal Court issued the latest in a series of decisions relating to the patent-eligibility of Aristocrat’s electronic gaming machine (EGM) patents. Unfortunately it does not resolve the legal uncertainty created by the High Court’s split decision on the matter in 2022. What next?
Leading Light Series: International Women’s Day 2024 | Spotlight on Pearce IP’s Julie Ballance – Special Counsel (NZ)
As a Women Owned and led boutique IP firm, where pay parity is a given, Pearce IP celebrates International Women’s Day and the diversity, equity and inclusion of which we are...
Leading Light Series: International Women’s Day 2024 | Spotlight on Pearce IP’s Jacinta Flattery-O’Brien PhD – Special Counsel
As a Women Owned and led boutique IP firm, where pay parity is a given, Pearce IP celebrates International Women’s Day and the diversity, equity and inclusion of which we are...
Leading Light Series: International Women’s Day 2024 | Spotlight on Pearce IP’s Kim Evans – Executive, Lawyer & Trade Mark Attorney
As a Women Owned and led boutique IP firm, where pay parity is a given, Pearce IP celebrates International Women’s Day and the diversity, equity and inclusion of which we are...
Still stuck in the mud
On 5 March 2024, the Australian Patent Office (APO) issued its decision in the opposition filed by Clearview Towing Mirrors Pty Ltd in respect of Australian patent application AU2020281026 (Opposed Application). Clearview had opposed the grant of the Opposed Application on the grounds of inventive step, novelty, sufficiency, support and clarity.
Leading Light Series: International Women’s Day 2024 | Spotlight on Pearce IP’s Executive Lawyer, Helen Macpherson
As a Women Owned and led boutique IP firm, where pay parity is a given, Pearce IP celebrates International Women’s Day and the diversity, equity and inclusion of which we are...
Leading Light Series: International Women’s Day 2024 | Spotlight on Pearce IP’s Deputy CEO & Head of Talent Adele Chadwick
As a Women Owned and led boutique IP firm, where pay parity is a given, Pearce IP celebrates International Women’s Day and the diversity, equity and inclusion of which we are...
Pearce IP BioBlast w/e 8 March 2024
9 MAR 2024 US | Samsung Bioepis Presents Interchangeability Updates for its Adalimumab and Ustekinumab Biosimilars at AAD On 9 March 2024, Samsung Bioepis presented two papers...
A bet both ways wins PTE for Ono for OPDIVO® (nivolumab) patent based on Merck’s KEYTRUDA® (pembrolizumab)
On 16 February 2024, IP Australia published that Ono Pharmaceutical Co. Ltd (Ono) was granted a patent term extension (PTE) in respect of its Australian Patent No. 2011203119 (Patent). This is the quiet conclusion to Ono’s dispute with the Patent Office relating to OPTIVO® (nivolumab) which culminated in an appeal court decision rejecting its previous application for PTE.
Leading Light Series: International Women’s Day 2024 | Spotlight on Pearce IP’s Founder Naomi Pearce
As a Women Owned and led boutique IP firm, where pay parity is a given, Pearce IP celebrates International Women’s Day and the diversity, equity and inclusion of which we are...
Leading Lights: Celebrating our Female Trailblazers on International Women’s Day 2024
International Women’s Day is a time to celebrate the achievements and progress of women around the world. It’s a day to reflect on the strides we’ve made towards gender equality and inclusion, whilst acknowledging the work that still lies ahead. We take a moment to spotlight some of the incredible women of Pearce IP.
Recent BioBlast® Updates
Get our Pearce IP Blogs & BioBlast® sent directly to your inbox
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.